REPLY: “From Cloud to Edge” Research Predicts the Rise of Edge Computing and Unveils the Main Trends in the Cloud Computing Market
2.2.2021 12:00:00 EET | Business Wire | Press release
By 2025 Cloud Computing will lead the ICT infrastructure market and Edge Computing will become an exponentially growing market, according to Reply’s new research “From Cloud to Edge”, made possible by Reply’s Trend SONAR proprietary data-driven platform and the support of Teknowlogy Group.
The research explores the use of both Cloud Computing and Edge Computing technologies in “Europe-5” (Italy, Germany, France, Netherlands, Belgium), and “Big-5” (USA, United Kingdom, Brazil, China, India) clusters in order to understand the evolution of the market.
In the next 5 five years Edge Computing will be an exponentially growing market in all “Europe-5” and “Big-5” clusters’ countries. Germany will be the biggest European market for both Cloud Computing and Edge Computing; the USA will be the dominant market worldwide.
The growing usage of IoT solutions, the closer combination of Information Technology and Operational Technology and the integration of Industrial Control Systems in the IT stack, as well as future 5G campus solutions for low-latency applications, are accelerating the need for edge solutions.
In fact, Edge Computing can support companies with computing tasks that cannot be done in the cloud and offers clear advantages when dealing with low latency, connectivity, security or privacy and transmitted data volumes are an issue.
Edge and distributed cloud architectures will increase the speed of data processing and reduce time lag. Edge computing, alone or in combination with Cloud Computing, will play a key role to enable technologies like autonomous vehicles, digital factories, smart cities, digital health, smart tracking and much more.
Hybrid models like Edge Cloud will be pushed by the hyperscalers and the wide 5G rollout will give Telcos and their service partners a relevant role in the new ecosystem, especially thanks to mobile-edge computing which is able to ensure very low latency without local infrastructure, with compute units not on-premise but extremely close from to a cell tower.
“Edge computing is here to stay. It is already starting to reshape enterprise computing and it can play a vital role in IT architectures. All the industries that need to perform the computing tasks as close to where data is gathered as possible will benefit from Edge Computing. At Reply, we’re already supporting global enterprises to design and implement architectures that leverage the best of Edge and Cloud Computing, while ensuring privacy and cybersecurity” commented Filippo Rizzante, CTO Reply.
In addition, the research indicates that Cloud Computing became the most popular ICT focus during Coronavirus peaks. COVID-19 has intensified the global spread of Cloud Computing technologies after 15 years of steady growth: across the world, millions of users started to use cloud-based platforms to collaborate, shop online, and for entertainment purposes.
Cloud technologies are key to being able to react and restart activities. By 2021 in both “Europe-5” and “Big-5” clusters the Infrastructure as a Service (IaaS)/Platform as a Service (PaaS) market will grow - in all scenarios - between 50% and 55% (vs. 2019).
The Software as a Service (SaaS) market is also set to grow rapidly in every country analysed. In particular, by 2025 it is predicted to double in the USA, UK and all “Europe-5” cluster countries, while likely to quadruple in India and China.
For more insights download the full research “From Cloud To Edge”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005054/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom